Press Release: Sanofi delivers first medicines from Global Health
Unit’s Impact brand portfolio
Sanofi delivers first medicines from Global
Health Unit’s Impact brand portfolio
Paris, October 19, 2023. Sanofi
has delivered the first medicines from its Global Health Unit’s
not-for-profit Impact brand portfolio to the Republic of Djibouti.
Enoxaparin Sodium Impact is an anticoagulant medicine indicated for
the treatment of venous thromboembolism including deep vein
thrombosis, a potentially lethal disease often underdiagnosed on
the African continent. With this first shipment to Djibouti, Sanofi
delivers on its commitment to improve and accelerate affordable and
sustainable access to quality medicines, vaccines and healthcare
for underserved populations.
Sanofi's social model to broaden access is
channeled through its Global Health Unit (GHU). The first global
initiative of its kind, Sanofi’s GHU aims to provide access to a
broad portfolio of medicines in 40 countries with the highest unmet
medical needs. To that point, the GHU created Impact, a unique
not-for-profit brand with 30 standard-of-care medicines produced by
Sanofi, some of which are considered "essential" by the World
Health Organization (WHO). The Impact medicines cover a wide range
of therapeutic areas, including diabetes, cardiovascular disease,
tuberculosis, malaria and cancer.
Jon FairestHead, Global Health
Unit, Sanofi“I'm delighted to see the very first Impact brand
medicine, Enoxaparin Sodium Impact, arrive on Djibouti soil. This
is an important milestone in Sanofi’s long-term objective to reach
2 million people with noncommunicable diseases in underserved
populations by 2030. But providing access to quality medicines and
sustainable healthcare to people in the 40 most underserved
countries is not a simple task. It requires cross-sector
partnerships on a global, regional, and importantly, on a local
scale – work Sanofi does on the ground with the GHU teams. After
Djibouti, we are now heading to Tanzania, scheduled to be the
second country to receive an Impact brand medicine: Insulin
Glargine Impact.”
The delivery of Enoxaparin Sodium Impact comes
months after the signature of a partnership with the Republic of
Djibouti’s Caisse Nationale de Sécurité Sociale (CNSS), the
national social security fund. The partnership aims at improving
diagnosis and management of cardiometabolic diseases and diabetes
in Djibouti and to help local communities gain sustainable access
to quality medicines at accessible pricing, medical training and
capacity building.
Deka Ahmed RoblehManaging
Director, Caisse Nationale de Sécurité Sociale, Djibouti“In
partnership with Sanofi’s Global Health Unit, we are working to
remove barriers that limit access to quality treatment and care for
noncommunicable disease patients in Djibouti. The availability of
Enoxaparin Sodium Impact at accessible pricing addresses an unmet
need in the management of venous thromboembolic disease, a
condition often underdiagnosed. Moreover, working with Sanofi
within the local community to help train healthcare professionals,
drive awareness around the management of cardiometabolic diseases
and diabetes, and build capacity is critical to improving patient
outcomes throughout the country.”
Ahead of the delivery of the first
not-for-profit Impact brand medicines, Sanofi’s Global Health Unit
has been working closely with local communities, authorities and
non-governmental organizations to support the set up and
development of sustainable healthcare systems for those who suffer
from chronic diseases and require complex care, and to develop
disease awareness programs. To date, over 1,800 healthcare
professionals have been trained in GHU-sponsored programs
globally.
Tanzania is scheduled to be the second country to
receive an Impact brand medicine : Insulin Glargine Impact
The WHO estimates over 4.5 billion people, or half
the world's population, lacks coverage for essential health
services1. According to the WHO, noncommunicable diseases (NCDs)
are responsible for 41 million people dying each year, with low-
and middle-income countries accounting for 77% of all NCDs
deaths2.About SanofiWe are an innovative global healthcare company,
driven by one purpose: we chase the miracles of science to improve
people’s lives. Our team, across some 100 countries, is dedicated
to transforming the practice of medicine by working to turn the
impossible into the possible. We provide potentially life-changing
treatment options and life-saving vaccine protection to millions of
people globally, while putting sustainability and social
responsibility at the center of our ambitions. Sanofi is listed on
EURONEXT: SAN and NASDAQ: SNY
Media RelationsVictor
Rouault | + 33 6 70 93 71 40
| victor.rouault@sanofi.comEvan Berland | +1
215 432 0234 | evan.berland@sanofi.comSandrine
Guendoul | + 33 6 25 09 14 25
| sandrine.guendoul@sanofi.com
Investor RelationsEva
Schaefer-Jansen | + 33 7 86 80 56 39
| eva.schaefer-jansen@sanofi.comArnaud
Delépine | + 33 6 73 69 36 93 |
arnaud.delepine@sanofi.comCorentine
Driancourt | + 33 6 40 56 92 21 |
corentine.driancourt@sanofi.comFelix
Lauscher | + 1 908 612 7239 |
felix.lauscher@sanofi.comTarik Elgoutni| + 1 617
710 3587 | tarik.elgoutni@sanofi.comNathalie
Pham | + 33 7 85 93 30 17 |
nathalie.pham@sanofi.com
Sanofi Forward-Looking
StatementsThis press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts. These statements include projections
and estimates regarding the marketing and other potential of the
product, or regarding potential future revenues from the product.
Forward-looking statements are generally identified by the words
“expects”, “anticipates”, “believes”, “intends”, “estimates”,
“plans” and similar expressions. Although Sanofi’s management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, unexpected regulatory actions or delays, or government
regulation generally, that could affect the availability or
commercial potential of the product, the fact that product may not
be commercially successful, the uncertainties inherent in research
and development, including future clinical data and analysis of
existing clinical data relating to the product, including post
marketing, unexpected safety, quality or manufacturing issues,
competition in general, risks associated with intellectual property
and any related future litigation and the ultimate outcome of such
litigation, and volatile economic and market conditions, and the
impact that pandemics or other global crises may have on us, our
customers, suppliers, vendors, and other business partners, and the
financial condition of any one of them, as well as on our employees
and on the global economy as a whole. The risks and uncertainties
also include the uncertainties discussed or identified in the
public filings with the SEC and the AMF made by Sanofi, including
those listed under “Risk Factors” and “Cautionary Statement
Regarding Forward-Looking Statements” in Sanofi’s annual report on
Form 20-F for the year ended December 31, 2022. Other than as
required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements.
1
https://www.who.int/news-room/fact-sheets/detail/universal-health-coverage-(uhc)2
https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases#SnippetTab
Sanofi (BIT:1SAN)
Historical Stock Chart
From May 2024 to Jun 2024
Sanofi (BIT:1SAN)
Historical Stock Chart
From Jun 2023 to Jun 2024